JP2012144538A5 - - Google Patents

Download PDF

Info

Publication number
JP2012144538A5
JP2012144538A5 JP2012040759A JP2012040759A JP2012144538A5 JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5 JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
tumor
antagonist
coded
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012040759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012144538A (ja
JP5719322B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012144538A publication Critical patent/JP2012144538A/ja
Publication of JP2012144538A5 publication Critical patent/JP2012144538A5/ja
Application granted granted Critical
Publication of JP5719322B2 publication Critical patent/JP5719322B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012040759A 2004-06-18 2012-02-27 腫瘍の治療 Expired - Lifetime JP5719322B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58074504P 2004-06-18 2004-06-18
US60/580,745 2004-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007516758A Division JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2012144538A JP2012144538A (ja) 2012-08-02
JP2012144538A5 true JP2012144538A5 (cg-RX-API-DMAC7.html) 2013-05-09
JP5719322B2 JP5719322B2 (ja) 2015-05-13

Family

ID=35351719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療
JP2012040759A Expired - Lifetime JP5719322B2 (ja) 2004-06-18 2012-02-27 腫瘍の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007516758A Expired - Lifetime JP5039544B2 (ja) 2004-06-18 2005-06-17 腫瘍の治療

Country Status (7)

Country Link
US (2) US8147827B2 (cg-RX-API-DMAC7.html)
EP (1) EP1786466B1 (cg-RX-API-DMAC7.html)
JP (2) JP5039544B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005265067B2 (cg-RX-API-DMAC7.html)
CA (1) CA2570887C (cg-RX-API-DMAC7.html)
ES (1) ES2429041T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006009805A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998255B1 (en) * 1999-09-24 2006-02-14 Solvay Pharmaceuticals B.V. Human G-protein coupled receptor
CA2618542A1 (en) * 2005-08-09 2007-02-15 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
US20080124329A1 (en) * 2006-07-05 2008-05-29 Schreiner George F Conditioned Cell Immunization
NZ578354A (en) * 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
WO2009147695A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP4686733B2 (ja) * 2008-06-02 2011-05-25 国立大学法人 東京大学 抗がん剤
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
JP2011074093A (ja) * 2008-06-02 2011-04-14 Univ Of Tokyo 抗がん剤
EP2421898B1 (en) 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
WO2012118806A2 (en) * 2011-02-28 2012-09-07 The Regents Of The University Of California Compositions and methods for detecting and treating cancer
JP5771123B2 (ja) * 2011-11-09 2015-08-26 株式会社 資生堂 プロフィラグリンc末端ドメイン特異的抗体及びその用途
JP2013235003A (ja) * 2012-05-10 2013-11-21 Fujita Gakuen 細胞におけるdna損傷の検出方法及びdna鎖切断応答性細胞表面抗原に対する抗体
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX2015014486A (es) 2013-04-15 2016-07-21 Regeneron Pharma Marcadores de respuesta de células tumorales a la terapia.
EP3024456A4 (en) * 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2020106049A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
EP2325321A1 (en) * 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6652853B2 (en) 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
JP2005505526A (ja) 2001-07-23 2005-02-24 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Ugt1a1に基づいたがんの改善治療の手段及び方法
WO2004091634A1 (en) 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists

Similar Documents

Publication Publication Date Title
JP2012144538A5 (cg-RX-API-DMAC7.html)
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
JP2012140442A5 (cg-RX-API-DMAC7.html)
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
IL232119A0 (en) Fetal chromosomal aneuploidy diagnosis
JP2014530840A5 (cg-RX-API-DMAC7.html)
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
Casals et al. Next-generation sequencing approaches for genetic mapping of complex diseases
WO2013188605A3 (en) Predictive markers for cancer and metabolic syndrome
JP2015518492A5 (cg-RX-API-DMAC7.html)
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
JP2014507563A5 (cg-RX-API-DMAC7.html)
JP2012101354A5 (cg-RX-API-DMAC7.html)
JP2010281322A5 (cg-RX-API-DMAC7.html)
IL233875A0 (en) A preparation and its use for the treatment of anal fissures
JP2012179231A5 (cg-RX-API-DMAC7.html)
CL2014003484A1 (es) Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.
JP2014529579A5 (cg-RX-API-DMAC7.html)
PT2670769T (pt) R2r1/2 em diagnóstico e terapêutica
JP2013059750A5 (cg-RX-API-DMAC7.html)
PL3027208T3 (pl) Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
JP2015508319A5 (cg-RX-API-DMAC7.html)
Humphreys The German Understanding of National History in the Hauptstadtdebatte
지선하 Cohort and prognosis study design